News

AVEREL: Avastin Defers Progression in HER2-Positive Metastatic Breast Cancer*

Publish date: December 8, 2011

 

FROM THE SAN ANTONIO BREAST CANCER SYMPOSIUM

*Correction, 12/9/11: An earlier version of this article incorrectly noted in the headline that Avastin improves breast cancer survival.

Pages

Recommended Reading

BOLERO-2: Everolimus Plus Exemestane Delays Breast Cancer Progression
MDedge Internal Medicine
Zoledronic Acid's Breast Cancer Benefit Extends 7 Years
MDedge Internal Medicine
FDA Drops Restrictions for Thrombocytopenia Treatments
MDedge Internal Medicine
IOM Dissects Environmental Risk Factors for Breast Cancer
MDedge Internal Medicine
Dual HER2 Blockade Defers Breast Cancer Progression
MDedge Internal Medicine
DCIS Assay Predicts Recurrence Risk After Breast Surgery
MDedge Internal Medicine
Clodronate Offered Modest Benefit for Breast Cancer Patients
MDedge Internal Medicine
Panel Endorses Surveillance for Low-Risk Prostate Cancer
MDedge Internal Medicine
Medicare Study Confirms Colonoscopy's Cancer Prevention Power
MDedge Internal Medicine
ZO-FAST: Immediate Zoledronic Acid Beats Delayed Tx in Early Breast Cancer
MDedge Internal Medicine